Continuous Glucose Monitoring Following Hospital Discharge

단계 해당 없음 진행 중(모집 완료) NCT05360056

요약

In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.

Change in TIR 70-180 mg/dl

12 weeks · percentage of time spent 70-180 mg/dl

% Wear Time >70%

12 weeks · Participants

DTSQc Score

12 weeks · score on a scale

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
• Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Uric Acid Lowering Trial in Youth Onset T2D — University of Colorado, Denver
• Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 — State University of New York at Buffalo
• Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on I — University of Colorado, Denver
• A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus — Eli Lilly and Company

전체 임상